PubRank

Marco Giovannini

Author PubWeight™ 123.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008 5.07
2 The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010 4.47
3 Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 2010 3.77
4 Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev 2005 3.59
5 NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 2003 2.55
6 A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system. Proc Natl Acad Sci U S A 2007 2.46
7 Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010 2.38
8 Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A 2003 2.16
9 A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 2004 1.85
10 MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 2012 1.83
11 Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab Invest 2004 1.82
12 Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leuk Lymphoma 2009 1.80
13 Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A 2013 1.72
14 Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 2007 1.71
15 Transfusions at home in patients with myelodysplastic syndromes. Leuk Res 2012 1.59
16 Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations. Dis Model Mech 2009 1.49
17 Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 2002 1.45
18 Bioluminescence imaging of live infected salmonids reveals that the fin bases are the major portal of entry for Novirhabdovirus. J Virol 2006 1.45
19 The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest 2009 1.44
20 Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002 1.43
21 Anticoagulant and Anti-thrombotic Treatments in the Management of Hematological Malignancies in a Home Care Program. Indian J Palliat Care 2011 1.42
22 CARD15/NOD2 is required for Peyer's patches homeostasis in mice. PLoS One 2007 1.41
23 Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO Rep 2005 1.41
24 Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009 1.41
25 Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004 1.31
26 Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 2011 1.24
27 Making quality of life assessment a dashboard for patient management. Support Care Cancer 2014 1.23
28 Cre-mediated germline mosaicism: a new transgenic mouse for the selective removal of residual markers from tri-lox conditional alleles. Nucleic Acids Res 2003 1.21
29 Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies. Ann Hematol 2011 1.15
30 WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development 2012 1.12
31 Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron 2003 1.12
32 Magnetic cell sorting for enriching Schwann cells from adult mouse peripheral nerves. J Neurosci Methods 2003 1.10
33 Home care management of patients affected by hematologic malignancies: a review. Haematologica 2006 1.10
34 Disability and physical rehabilitation in patients with advanced hematological malignancies followed in a home care program. Support Care Cancer 2009 1.05
35 Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res 2010 1.04
36 A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clin Exp Metastasis 2007 1.02
37 Characterization of the axon initial segment (AIS) of motor neurons and identification of a para-AIS and a juxtapara-AIS, organized by protein 4.1B. BMC Biol 2011 1.02
38 The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol 2008 1.01
39 Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci 2013 1.01
40 Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators. Development 2013 1.00
41 Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem 2002 0.98
42 Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 2003 0.98
43 Protein 4.1B contributes to the organization of peripheral myelinated axons. PLoS One 2011 0.98
44 Mouse models of neurofibromatosis 1 and 2. Neoplasia 2002 0.98
45 Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther 2006 0.97
46 Nod2 mediates susceptibility to Yersinia pseudotuberculosis in mice. PLoS One 2008 0.97
47 Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer 2009 0.95
48 Novel features of boundary cap cells revealed by the analysis of newly identified molecular markers. Glia 2009 0.95
49 NOD2: a potential target for regulating liver injury. Lab Invest 2008 0.95
50 Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. PLoS One 2011 0.94
51 Long-lasting remission induced by rituximab in two cases of refractory autoimmune haemolytic anaemia due to cold agglutinins. Blood Transfus 2009 0.94
52 Tumor-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells. J Cell Sci 2009 0.92
53 The tumor suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton. Hum Mol Genet 2007 0.91
54 Management of hematological malignancies in patients affected by renal failure. Expert Rev Anticancer Ther 2011 0.91
55 Motor disability, clinical complications, quality of life, and survival in patients with cancer: a plausible scenario. Support Care Cancer 2014 0.91
56 Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 2005 0.89
57 Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression. Sci Signal 2011 0.89
58 Pure red cell aplasia associated with hemolytic anemia refractory to standard measures and resolved by rituximab in an elderly patient. Int J Hematol 2008 0.89
59 Tumor suppressor schwannomin/merlin is critical for the organization of Schwann cell contacts in peripheral nerves. J Neurosci 2008 0.88
60 Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol 2007 0.88
61 Association of Caspr/paranodin with tumour suppressor schwannomin/merlin and beta1 integrin in the central nervous system. J Neurochem 2003 0.87
62 Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. Blood Res 2013 0.87
63 The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 2010 0.87
64 Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor. Protein Sci 2011 0.87
65 Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 2002 0.86
66 Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin. Oncogene 2004 0.85
67 Back to the future: proceedings from the 2010 NF Conference. Am J Med Genet A 2010 0.84
68 Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res 2013 0.84
69 Idiopathic thrombocytopenic purpura coexisting with polycythemia vera. Asian J Transfus Sci 2011 0.84
70 The management of membranous glomerulopathy in allogeneic stem cells transplantation: updated literature. Cardiovasc Hematol Agents Med Chem 2013 0.84
71 Pain in blood cancers. Indian J Palliat Care 2011 0.83
72 The tumor suppressor merlin is required for cell cycle exit, terminal differentiation, and cell polarity in the developing murine lens. Invest Ophthalmol Vis Sci 2010 0.83
73 Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab. Ann Hematol 2013 0.83
74 Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders. Support Care Cancer 2014 0.82
75 Tattoo related pyoderma/ectyma gangrenous as presenting feature of relapsed acute myeloid leukaemia: an exceptionally rare observation. Injury 2011 0.82
76 Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting. Acta Haematol 2014 0.82
77 Pain management in multiple myeloma. Expert Rev Anticancer Ther 2010 0.82
78 Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003 0.82
79 Managing myelodysplastic syndromes in very old patients: a teaching case report. Clin Interv Aging 2013 0.81
80 Palifermin in the management of mucositis in hematological malignancies: current evidences and future perspectives. Cardiovasc Hematol Agents Med Chem 2009 0.81
81 Complex and multifaceted therapy-related myeloid neoplasm following laryngeal cancer treated with Cisplatin and radiotherapy. Mediterr J Hematol Infect Dis 2013 0.81
82 CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A 2014 0.81
83 Bone marrow necrosis as a terminal complication of a very long-lasting polycythemia vera. Int J Hematol 2007 0.81
84 Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol 2011 0.81
85 Motor disability in malignant hematology: an epidemiological study on Italian hospitalized patients. Leuk Res 2009 0.81
86 Pain syndromes in haematological malignancies: an overview. Hematol J 2004 0.80
87 Opioids in pain management of blood-related malignancies. Ann Hematol 2006 0.79
88 Epidemiology and pathogenesis of incident pain-related disability in malignant hematology: an Italian survey. Ann Hematol 2010 0.79
89 Gingival myeloid sarcoma in myelodysplastic syndrome. Support Care Cancer 2013 0.78
90 Long-term survival of a patient with bone marrow gelatinous degeneration of idiopathic origin. Korean J Hematol 2012 0.78
91 Motor disability in the setting of oral anticoagulant therapy. Int J Hematol 2011 0.78
92 Update from the 2013 International Neurofibromatosis Conference. Am J Med Genet A 2014 0.78
93 Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 2015 0.77
94 Meningioma mouse models. J Neurooncol 2010 0.77
95 [Opioid analgesics in patients with chronic renal failure: principles for use and current guidelines]. G Ital Nefrol 2011 0.77
96 Authors' reply. Indian J Palliat Care 2011 0.76
97 Controversies on antibiotic lock technique duration: experience with a 3-day course for hematological patients. Infect Control Hosp Epidemiol 2011 0.76
98 IgG secreting lymphoplasmacytoid leukemia with massive skin involvement and very aggressive clinical course: an exceptionally rare observation. Leuk Res 2009 0.76
99 The prevention of oral mucositis in patients with blood cancers: current concepts and emerging landscapes. Cardiovasc Hematol Agents Med Chem 2012 0.76
100 Epidemiology of pain in hospital haematological setting: an Italian survey. Leuk Res 2007 0.76
101 Mouse models of human cancer consortium symposium on nervous system tumors. Cancer Res 2003 0.76
102 [Membranous glomerulonephritis secondary to allogeneic stem cell transplant: review of the literature]. G Ital Nefrol 2012 0.76
103 Sleep complaints in hospitalized Italian patients with hematological malignancies. Intern Med 2010 0.75
104 Single versus double-unit transfusion policy in hematology. Haematologica 2012 0.75
105 IgA-induced autoimmune hemolytic anemia in a patient with antiphospholipid syndrome. Asian J Transfus Sci 2012 0.75
106 Management of Peritoneal Dialysis within a Home Care Program for Hematological Malignancies: Concerns and Perspectives Illustrated by a Case Report. Indian J Palliat Care 2011 0.75
107 Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells. Cancer 2003 0.75
108 Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency. Turk J Haematol 2016 0.75
109 Dysgeusia in patients with hematological malignancies: a reminder for hematologist. J Oral Pathol Med 2012 0.75
110 Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma. Ann Hematol 2008 0.75
111 Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures. Herpes 2007 0.75
112 Koebner's phenomenon as a rare mechanism of acute myeloid leukemia dissemination: report of two cases with a brief overview. Support Care Cancer 2010 0.75
113 Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy. Cardiovasc Hematol Agents Med Chem 2016 0.75
114 Necrotizing fasciitis in myelodysplastic syndrome: an exceptionally rare occurrence. Support Care Cancer 2012 0.75
115 Fever of unknown origin, anemia and thrombocytosis as early symptoms and signs of a late-onset polymialgia rheumatica: a diagnostic challenge. Ann Saudi Med 2012 0.75
116 Rapid response and sustained remission by rituximab in four cases of plasma-exchange-failed acute thrombotic thrombocytopenic purpura. Int J Hematol 2009 0.75
117 Palliative sedation therapy in a bone marrow transplant unit. Support Care Cancer 2008 0.75
118 Isolated bone involvement of a single lumbar vertebra body as unusual presentation of relapsing Hodgkin's lymphoma. Acta Oncol 2009 0.75
119 Long-lasting remission of a relapsed large cell non-Hodgkin's lymphoma by Y90 ibritumomab tiuxetan as salvage therapy. Tumori 2009 0.75
120 Motor disability in end-stage renal failure: an epidemiological study on Italian dialyzed patients. Saudi J Kidney Dis Transpl 2011 0.75
121 Pancytopenia and severe sepsis in an adult case of congenital X-linked agammaglobulinemia (XLA). Ann Hematol 2010 0.75
122 Magnetic resonance coronary angiography: present clinical applications. Ital Heart J 2002 0.75
123 Bortezomib-related colon mucositis in a multiple myeloma patient. Support Care Cancer 2009 0.75
124 Pain management in hematological patients with major organ dysfunctions and comorbid illnesses. Cardiovasc Hematol Agents Med Chem 2012 0.75
125 Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and acute myeloid leukaemia in an elderly patient: complete remissions of both diseases by rituximab-bendamustine regimen combined to hypomethylating therapy. J Chemother 2013 0.75
126 Multicentric myeloid/NK sarcoma in an aleukemic patient evolved in refractory acute leukemia. Leuk Res 2009 0.75
127 Vinorelbine and gemcitabine as salvage treatment in advanced and very poor prognosis non-Hodgkin's lymphoma patients. Ann Hematol 2007 0.75
128 [Bioluminescent imaging to monitor tumor progression and metastasis in live animal]. J Soc Biol 2007 0.75
129 Caring for terminal patients in haematology: the urgent need of a new research agenda. Support Care Cancer 2014 0.75
130 Fulminant thrombotic microangiopathy as a clinical presentation of an occult signet-ring cell carcinoma of the lung and misdiagnosed as idiopathic thrombotic thrombocytopenic purpura. Saudi Med J 2010 0.75
131 Unusual sequence of lymphoid disorders: follicular lymphoma subsequent to Hodgkin lymphoma and transformed into diffuse large B-cells non Hodgkin lymphoma. Acta Oncol 2009 0.75
132 Primary anaplastic large B-cell lymphoma in mandible: Long-term complete remission with R-CHOP regimen and involved field radiotherapy. Oral Oncol 2009 0.75
133 Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis. Cancer Chemother Pharmacol 2008 0.75
134 Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes. Support Care Cancer 2013 0.75